- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03872284
Neuro-ophthalmology and Autoimmune Encephalitis (NODE) (NODE)
January 25, 2024 updated by: Hospices Civils de Lyon
Study of Neuro-ophthalmology Disorders in Autoimmune Encephalitis (NODE)
Autoimmune encephalitis represents a group of rare and heterogeneous neurological disorders.
Pathophysiological mechanisms in these diseases are still unknown.
Recently, oculomotor and neurovisual disorders have been described.
Cerebral areas and neuronal networks associated with these abnormalities are well described.
The investigator proposes to study and describe such neuro-ophthalmological disorders in a prospective cohort of patients with a autoimmune encephalitis, to better understand the pathophysiological basis of this neurological condition.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Study Type
Observational
Enrollment (Estimated)
70
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Caroline Tilikete, Prof.
- Phone Number: 33 4 72 11 93 84
- Email: caroline.tilikete@chu-lyon.fr
Study Locations
-
-
-
Bron, France, 69500
- Recruiting
- Hospices Civils de LYON
-
Contact:
- Caroline TILIKETE, MD
- Email: caroline.tilikete@inserm.fr
-
Principal Investigator:
- Caroline TILIKETE, MD
-
Sub-Investigator:
- Aude METZGER, MD
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 70 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Sampling Method
Non-Probability Sample
Study Population
Men and women 18 to 70 years old diagnosed with autoimmune encephalitis
Description
Inclusion Criteria:
- Diagnosis of autoimmune encephalitis
- With or without pathological antibody
- Aged from 18 to 70 years old
- Able to understand the aims and methods of this project
- Non opposed to the participation of this study
Exclusion Criteria:
- Other neurological, psychiatric or systemic conditions, which could induce neuro-ophthalmological signs Cognitive impairment, which is not linked to autoimmune encephalitis
- Ophthalmological condition, which could modify the interpretation of neuro-ophthalmological data Inability to remain seated
- Pregnancy or breast feeding
- Adults under guardianship
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
1
Patients in the study group have a diagnosis of autoimmune encephalitis, are 18 to 70 years old, and have no significant comorbidity such as psychiatric, neurological conditions and able to understand the aim of this study.
|
Each participant will have a neurovisual assessment and an oculomotor movement recording with an eye tracker (infra red cameras).
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percentage of patients presenting a neuro-ophthalmological abnormality.
Time Frame: Day 0
|
A neuro-ophthalmological disorder is defined as an abnormality in the oculo-motor movement recording or/and the presence of a neurovisual impairment.
|
Day 0
|
Percentage of patients presenting neuro-ophthalmological abnormality.
Time Frame: At 6 months if an abnormality is found
|
A neuro-ophthalmological disorder is defined as an abnormality in the oculo-motor movement recording or/and the presence of a neurovisual impairment.
|
At 6 months if an abnormality is found
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Caroline Tilikete, Prof., Department of neuro-ophthalmology, Pierre Wertheimer university hospital
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
January 22, 2020
Primary Completion (Estimated)
January 24, 2027
Study Completion (Estimated)
January 24, 2027
Study Registration Dates
First Submitted
March 11, 2019
First Submitted That Met QC Criteria
March 11, 2019
First Posted (Actual)
March 13, 2019
Study Record Updates
Last Update Posted (Actual)
January 26, 2024
Last Update Submitted That Met QC Criteria
January 25, 2024
Last Verified
January 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 69HCL18_0749
- 2019-A00684-53 (Other Identifier: ID RDB)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Autoimmune Encephalitis
-
Hoffmann-La RocheChugai Pharmaceutical Co.RecruitingNMDAR Autoimmune Encephalitis | LGI1 Autoimmune EncephalitisUnited States, Korea, Republic of, China, Japan, Czechia, Italy, Poland, Brazil, Argentina, Netherlands, Taiwan, France, Austria, Denmark, Ghana
-
Seoul National University HospitalWithdrawnAutoimmune EncephalopathyKorea, Republic of
-
Hospices Civils de LyonCompletedAutoimmune EncephalitisFrance
-
Medical University of ViennaCompletedPost Other Specified Vaccination EncephalitisAustria
-
Seoul National University HospitalCompletedEncephalitis
-
Hospices Civils de LyonCompletedAutoimmune EncephalitisFrance
-
Hospices Civils de LyonCompleted
-
University of BernNovartis; University Hospital Inselspital, Berne; Schweizerische Multiple Sklerose... and other collaboratorsRecruitingMultiple Sclerosis | Optic Neuritis | Neuromyelitis Optica Spectrum Disorder | CNS Sarcoidosis | CNS Vasculitis | Transverse Myelitis | Rasmussen Encephalitis | Acute Disseminated Encephalomyelitis | Anti-NMDAR Encephalitis | Anti-GAD65 Associated Autoimmune Encephalitis | Anti-AMPAR-1/2 Associated Autoimmune... and other conditionsSwitzerland
-
University Hospital, Strasbourg, FranceCompletedAcute Autoimmune EncephalitisFrance
-
Hospices Civils de LyonUnknownAutoimmune Encephalitis | Anti NMDA Receptor Encephalitis | Herpetic EncephalitisFrance
Clinical Trials on oculomotor movement recordings, neurovisual assessment
-
Centre Hospitalier Universitaire de Pointe-a-PitreGroupe Hospitalier Pitie-Salpetriere; University Hospital Center of MartiniqueCompletedProgressive Supranuclear Palsy
-
Women and Infants Hospital of Rhode IslandCompletedAdolescent Behavior | Language Development | Development, Child | Language Delay
-
IRCCS Eugenio MedeaRecruitingAutism Spectrum Disorder | Infant DevelopmentItaly
-
Shirley Ryan AbilityLabActive, not recruiting
-
Sheba Medical CenterUnknownHealthy Volunteers | Effect of CPAP on Chest MovementIsrael
-
Centre Hospitalier Universitaire de BesanconCompleted
-
Dina Tharwat mohamed aliUnknownMovement Disorders
-
Hacettepe UniversityCompletedMuscular Endurance And Its Association With Neck Pain, Disability, Neck Awareness, And KinesiophobiaCervical Disc HerniationTurkey
-
Massachusetts Eye and Ear InfirmaryBoston Children's Hospital; University of WashingtonRecruiting
-
Yeditepe UniversityEnrolling by invitationSpine Injury | Movement, Abnormal | Postural Lordosis | Cervical Lordosis | Postural KyphosisTurkey